ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.18, Zacks reports.
ArriVent BioPharma Stock Performance
ArriVent BioPharma stock opened at $22.03 on Tuesday. The firm’s 50-day moving average is $26.58 and its 200-day moving average is $27.18. ArriVent BioPharma has a 1 year low of $14.35 and a 1 year high of $36.37.
Analysts Set New Price Targets
Separately, HC Wainwright upped their target price on shares of ArriVent BioPharma from $36.00 to $39.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd.
ArriVent BioPharma Company Profile
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Featured Articles
- Five stocks we like better than ArriVent BioPharma
- EV Stocks and How to Profit from Them
- Warren Buffett Sold ULTA Stock—But Should You?
- Expert Stock Trading Psychology Tips
- 3 Actively Managed ETFs Outperforming Despite Their Higher Fees
- 10 Best Airline Stocks to Buy
- Monster Beverage: Monster Upside or a Risky Buy?
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
